Genetically modified EBV-specific CTLs induce regression of EBV-lymphoma despite immunosuppression.
INTRODUCTION

Epstein-Barr virus (EBV) is a human -herpes virus infecting and establishing latency in
B-lymphocytes in more than 90% of adults. In healthy individuals EBV-specific Cytotoxic T Lymphocytes (CTL) prevent the outgrowth of the EBV-transformed B cells 1 . In hematopoietic stem cell (SCT) or solid organ transplantation (SOT) recipients, this T-cell immune surveillance is compromised by the immunosuppressive medication used to prevent GVHD/graft rejection.
This can enable uncontrolled proliferation and malignant transformation of EBV-infected Bcells, resulting in post-transplant lymphoproliferative diseases (PTLD). The prevalence of this complication in SOT can vary from 1-30%, depending on the organ transplanted, patient age and the intensity of immunosuppression 2 .
Therapies targeting EBV-infected B cells with monoclonal anti-CD20 antibodies (Rituximab), reduction of immunosuppressive drugs and chemotherapy are currently used 3, 4 but are often ineffective and have substantial toxicity. Rituximab as monotherapy is associated with high rate of disease progression and relapse 5 ; reduction of immunosuppression frequently results in graft rejection 6 , and while chemotherapy results in better response rates, treatment related mortality is high in this patient population 7 . In the PTLD-1 trial 8 combining Rituximab with CHOP chemotherapy, 3 year progression-free survival was 54%. Thus novel therapies are clearly needed.
Adoptive transfer of ex vivo-derived EBV-specific cytotoxic T-cells (EBV-CTL) to
reconstitute immunity to EBV 9-12 is a logical approach to the treatment of PTLD. However, the application of this approach for the treatment of PTLD in SOT patients, although feasible 10, 13, 14 , has been challenging. This difference is likely to reflect the need for the ongoing immunosuppression to prevent graft-rejection post SOT which inhibits virus-specific T cell responses 15, 16 . While it is generally possible to withdraw other immunosuppressive medication (eg MMF) to facilitate CTL function in SOT recipients developing PTLD, reduction in calcineurin inhibitors, the most critical immunosuppressive drugs used after SOT, frequently results in graft rejection. Indeed, in a major study, graft rejection was as common a cause of mortality in PTLD patients as the disease itself 6 .
To address this problem, we have previously developed a strategy for genetically engineering EBV-CTLs to be resistant to the calcineurin inhibitors, Cyclosporin A (CsA) and Tacrolimus (FK506) 17 . These drugs exert their immunosuppressive function by binding to 
MATERIALS AND METHODS
Generation of LCLs and EBV CTLs
Peripheral blood was taken from healthy EBV-seropositive volunteers after informed consent and PBMCs were isolated by Ficoll centrifugation (GE Healthcare, Amersham, UK).
EBV-LCLs were generated by infection of PBMCs with B95.8 supernatant as previously described 15 . EBV-CTLs were generated by repetitive stimulation of PBMC with autologous irradiated LCL as previously published 15 .
Generation of retrovirus and transduction
High-titre stable SFG retroviral supernatants carrying either the eGFP transgene alone or expressed with the CNA12 mutant pseudotyped with the RD114 envelope were produced as described previously 17 and were used to transduce EBV-CTL. LCLs were transduced with an SFG retroviral vector encoding Firefly Luciferase (FLuc-eBFP) to facilitate imaging.
Phenotypical and functional analysis of transduced CTLs.
CNA12eGFP or eGFP-EBV-CTL were assessed for phenotypic analysis by flow cytometry and for functionality using 51 Cr release, 3 H proliferation and IFN- ELISA assays in the presence/absence of 10ng/ml FK506 as detailed in Supplementary Materials and Methods.
Xenograft model and bioluminescence imaging.
NSG mice were obtained from Jackson Laboratory and raised under specific pathogenfree conditions. Mice were inoculated with 5×10 6 EBV-LCLs engineered to express firefly Luciferase (F-Luc) subcutaneously on the nape of the neck on day 0 (4 mice/cohort in 2 separate experiments 18 . In addition to monitoring with bioluminescence imaging, the size of LCL tumors was also assessed twice weekly with caliper measurement. Tumours were resected immediately after euthanasia for immunofluorescence staining.
Immunofluorescence.
Double-immunofluorescence was performed on formalin-fixed, paraffin-embedded tumour sections. Staining was carried out for B and T cells using a 1:100 dilution of primary rabbit monoclonal antibody specific for human CD3 and 1:20 dilution of primary mouse monoclonal antibody for human CD20 (Abcam, Cambridge, UK). This was followed by incubation with secondary antibodies, FITC anti-rabbit IgG and TRITC anti mouse IgG, respectively. Sections were viewed with epifluorescence using a Leica DM400B microscope and digitally captured using Metamorph software (Molecular Device, USA).
Statistical analysis
Mean ± SEM is depicted in all graphs. Statistical significance was determined by 2-way ANOVA followed by Bonferroni post-test for longitudinal data. Two-tailed Student's t-test for unpaired samples was applied to evaluate persistence of transferred T cells, CNA12 mutant expression, proliferation, cytokine secretion, and specific cytolysis at single time points. Survival curves were plotted according to the Kaplan-Meier method, and treatment groups compared using log-rank (Mantel-Cox) test analyses. Differences were considered significant for p values <0.05.
RESULTS
Characterisation of EBV-CTLs before infusion.
To investigate the ability of EBV-CTL genetically engineered to be resistant to calcineurin inhibitors to function in vivo despite on-going immunosuppression, we first Culture of either CNA12 or eGFP CTLs with FK506 before or during the cytotoxicity assay had no effect on the cytotoxicity of EBV-CTL against LCL targets (data not shown).
Taken together, these data show that the CNA12 transduced CTL infused in murine experiments were able to secrete cytokines/proliferate in response to EBV and lyse EBV infected targets in vitro despite the presence of FK506.
EBV-CTLs transduced with CN mutant lack alloreactivity.
If Tacrolimus resistant CTL are to be used clinically after organ transplant, it is critical that they are depleted of alloreactivity in order to avoid toxicity to the organ graft. We therefore assayed the proliferative responses of unselected and GFP + sorted CNA12-CTL to HLAmismatched allogeneic PBMC stimulators, comparing this with the alloreactivity of unmanipulated PBMC from the same donor. As shown in Figure 2 , unmanipulated donor PBMCs proliferated strongly in response to stimulation with irradiated, allogeneic PBMC (p<0.001). In contrast, the response of both unselected and GFP + sorted CNA12-CTL to allogeneic PBMCs was negligible, indicating that the process of EBV-CTL generation, expansion and transduction with CNA12 depletes alloreactivity.
Adoptive transfer of autologous Calcineurin resistant EBV-CTLs induced rejection of EBV-lymphoma in xenografted NSG mice in the presence of FK-506.
To determine whether CNA12 transduced CTL could mediate rejection of EBV + lymphoma in vivo despite the presence of immunosuppression, we adoptively transferred CNA12
or eGFP CTL into NSG mice bearing autologous EBV + F-Luc + LCL tumours in the presence or absence of FK506 (Experimental schema shown in Figure 3 ).
In vivo imaging showed tumour growth in the control mice treated with B-LCL within 20 days, requiring mice to be sacrificed (Figures 4a and 4b Figure 4a) .
In order to make our approach more feasible for clinical application, we have developed a simpler, more rapid methodology for generation of tacrolimus-resistant EBV-specific T cells using IFN- selection after stimulation with immunodominant EBV peptides followed by transduction with a retroviral vector encoding the CNA12 mutant 20 . As shown in Similar results were observed in mice treated with CNA12 CTLs generated using IFN- selection which were able to persist in vivo beyond 60 days after adoptive transfer in the presence of FK506 (Supplementary Figure 2a and 
b).
These data suggest that EBV-CTL genetically engineered to express CNA12 showed improved expansion, growth advantage and are able to persist in vivo in the presence of FK506 beyond 2 months post adoptive transfer.
Calcineurin resistant EBV CTLs infiltrate the tumour in the presence of FK506
We next investigated the ability of transduced EBV-CTL to home to LCL tumours in vivo using immunofluorescence analysis 40 days after CTL administration. In the absence of FK506, both CNA12 and eGFP transduced CTL homed well to the tumour, mediating regression ( Figure 7a ). Consistent with the increased persistence of CNA12-CTLs in the peripheral blood in the presence of FK506, we observed robust accumulation and infiltration of tumour infiltrating T lymphocytes (human CD3 + ) in regressed B-cell lymphoma, whereas very few human CD3 + T cells were detected in tumours resected at the same time from mice that received eGFP-CTL cells.
Calcineurin resistant EBV-CTLs do not infiltrate and do not induce toxicity in organs.
Histological examination showed no human T-cell infiltration or histological evidence of toxicity in brain, lungs, heart, kidneys, intestine and liver of the mice sacrificed 40 days after injection of CNA12-CTL (Figure 7b) , demonstrating that FK506 resistant CTL do not mediate off target organ toxicity in this model.
DISCUSSION
Adoptive immunotherapy with T-cell directed against tumor-specific or tumorassociated antigens represents a novel strategy for the treatment of human malignancies with a great clinical potential [21] [22] [23] [24] [25] . Adoptive transfer of ex-vivo derived EBV specific CTLs to reconstitute EBV-specific T cell immunity 3,26 is a logical approach for patients developing PTLD. This disease represents an ideal target for adoptive T-cell therapy because of the high level expression of immunogenic antigens from EBV presented by excellent antigen-presenting cells. The application of this approach has been shown to be extremely effective for PTLD arising after SCT, where immunosuppressive therapy can be reduced or suspended completely before EBV-CTLs administration 11, 27, 28 . In contrast in the SOT setting, although possible 10, 13, 14 , the approach has been limited by the need for life-long immunosuppressive therapy to avoid rejection of the transplanted organ which inhibits the proliferation, expansion and persistence of transferred EBV-CTL 15, 16 . For example in the study of Savoldo et al 10 , where autologous EBV CTL were infused in 12 SOT patients with EBV viremia only 1 patient cleared viremia, the in vivo expansion of infused EBV-CTL was poor (1.5-4.8 fold) and the frequency of circulating EBV-CTL returned to pre-infusion levels in all patients within 2 months of infusion.
To overcome this problem, we have previously generated EBV-specific CTLs which are resistant to the Calcineurin inhibitors Tacrolimus and Ciclosporin and have demonstrated their ability to function in vitro despite the presence of immunosuppression 17 .
In order to translate novel T-cell therapy approaches from bench to bedside, in vivo Currently we are in process of validating production of FK506 resistant EBV-CTL using this methodology under GMP conditions. We envision resistant CTL could be used as adjuvant therapy following Rituximab to improve response rates and prevent rejection without the need for chemotherapy which is poorly tolerated in SOT patients. Importantly, such an approach would obviate the need for reduction in immunosuppression, reducing the risk of graft rejection which is a major cause of mortality in PTLD patients. Given that the cost of generating transduced EBV-CTL is approximately $15,000; such an approach could potentially have major health economic benefits by avoiding the need for prolonged admission for chemotherapy and reducing the risk of graft rejection. In terms of toxicity, we have shown that CNA12 transduced EBV-CTL have negligible alloreactivity against HLA mismatched targets, suggesting they should have no detrimental effect on the organ graft. This is likely to reflect depletion of alloreactive T cells during the process of CTL culture and our data suggest that selection of retrovirally transduced CTL is not necessary to abrogate alloreactivity. Indeed, no graft toxicity was observed in previous clinical studies with either autologous or 3 rd party CTL 12, 32 . Since CTL are autologously derived, they should not cause off target toxicity to the host and, consistent with this, in our experiments no organ toxicity was observed in mice receiving FK506 resistant EBV-CTL. Importantly, since transduced EBV-CTLs are terminally differentiated, retroviral gene transfer is extremely unlikely to result in leukaemogenesis. As a safety strategy, in our model we have genetically modified EBV-CTLs with a CN mutant conferring resistance to Tacrolimus only, allowing suppression of the infused T cells with Cyclosporin in case of toxicity.
Overall, our findings provide strong support for the clinical application of calcineurin inhibitor resistant EBV-CTL as adjuvant therapy for SOT patients developing PTLD. Based on this work, we are now proceeding to a "double marking" clinical study in which such patients will be treated with both autologous CNA12 transduced and control EBV-CTL generated using our simplified methodology 20 
